In Brief: Henney's candidacy for FDA commissioner
This article was originally published in The Gray Sheet
Henney's candidacy for FDA commissioner: Return of Congress is logical time for the Clinton Administration to go public with the expected nomination of University of New Mexico VP-Health Sciences Jane Henney to be FDA commissioner. During the long Congressional recess, the administration had nothing to gain by nominating a candidate and giving any critics a free chance to build opposition. Albuquerque Journal picked up the possibility of Henney's return in a Jan. 21 article; other western dailies including L.A. Times are also running pre-appointment stories. Potential delays to the nomination include the protocol of waiting for nomination of the Surgeon General and distraction of the White House by the Lewinski scandal...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.